Sonoma Pharmaceuticals, Inc. (SNOA)
1.21
-0.02
(-1.63%)
USD |
NASDAQ |
Oct 07, 16:00
1.19
-0.02
(-1.65%)
After-Hours: 20:00
Sonoma Pharmaceuticals Enterprise Value : 1.288M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 1.288M |
| October 05, 2026 | 1.240M |
| October 02, 2026 | 1.335M |
| October 01, 2026 | 1.383M |
| September 30, 2026 | 1.527M |
| September 29, 2026 | 1.359M |
| September 28, 2026 | 1.431M |
| September 25, 2026 | 1.479M |
| September 24, 2026 | 1.359M |
| September 23, 2026 | 1.383M |
| September 22, 2026 | 1.599M |
| September 21, 2026 | 1.383M |
| September 18, 2026 | 1.527M |
| September 17, 2026 | 1.431M |
| September 16, 2026 | 1.288M |
| September 15, 2026 | 1.527M |
| September 14, 2026 | 1.575M |
| September 11, 2026 | 1.646M |
| September 10, 2026 | 1.670M |
| September 09, 2026 | 1.622M |
| September 08, 2026 | 1.766M |
| September 04, 2026 | 1.742M |
| September 03, 2026 | 1.718M |
| September 02, 2026 | 1.575M |
| September 01, 2026 | 1.575M |
| Date | Value |
|---|---|
| August 31, 2026 | 1.575M |
| August 28, 2026 | 1.670M |
| August 27, 2026 | 1.766M |
| August 26, 2026 | 2.005M |
| August 25, 2026 | 1.862M |
| August 24, 2026 | 1.814M |
| August 21, 2026 | 1.814M |
| August 20, 2026 | 1.814M |
| August 19, 2026 | 1.910M |
| August 18, 2026 | 1.622M |
| August 17, 2026 | 1.718M |
| August 14, 2026 | 1.622M |
| August 13, 2026 | 1.814M |
| August 12, 2026 | 1.958M |
| August 11, 2026 | 1.958M |
| August 10, 2026 | 1.575M |
| August 07, 2026 | 2.293M |
| August 06, 2026 | 1.383M |
| August 05, 2026 | 0.809M |
| August 04, 2026 | 1.144M |
| August 03, 2026 | 0.7611M |
| July 31, 2026 | 0.6654M |
| July 30, 2026 | 0.809M |
| July 29, 2026 | 0.6654M |
| July 28, 2026 | 0.8568M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.878B |
| Corcept Therapeutics, Inc. | 12.61B |
| Veru, Inc. | 19.01M |
| Johnson & Johnson | 641.85B |
| Eli Lilly & Co. | 1.136T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.33M |
| Revenue (Quarterly) | 6.406M |
| Total Expenses (Quarterly) | 6.736M |
| EPS Diluted (Quarterly) | -0.0858 |
| Gross Profit Margin (Quarterly) | 40.23% |
| Profit Margin (Quarterly) | -5.15% |
| Earnings Yield | -100.6% |
| Normalized Earnings Yield | -100.63 |